Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ranizurel is a biosimilar of ranibizumab, a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment that selectively binds to and inhibits the biological activity of human vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it prevents abnormal blood vessel growth and leakage in the eye. This mechanism helps treat vision loss associated with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization (mCNV), and macular edema following retinal vein occlusion. Ranizurel is administered as an intravitreal injection by an ophthalmologist[2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ranizurel.